Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 179 for “"Checkpoint Inhibitor"”.
-
Defining immune mechanisms underlying checkpoint inhibitor-induced inflammatory syndromes
… One important breakthrough has been the use of checkpoint inhibitors (CPIs) for the treatment of solid tumours. CPIs targeting the CTLA-4 and PD-1/PD-L1 T cell inhibitory pathways reverse tumour-induced immune suppression of T cells, promoting T cell-driven anti-tumour responses. One major …
-
Bridging Targeted Radionuclide and Checkpoint Inhibitor Therapies: Joining Forces
Radboud University, 10 november 2025
-
Outcomes of Immune Checkpoint Inhibitor-Mediated Colitis: Multicenter Cohort Study
Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious toxicity. Multiple reports have described the clinical presentation and course of IMC based on limited data. This was a collaborative effort from several cancer institutes to investigate features and outcomes of IMC. …
-
Immune checkpoint inhibitor-induced inflammatory arthritis: a single center review
INTRODUCTION: Immune checkpoint inhibitors are a new form of immunotherapy that has transformed the treatment landscape for an ever-increasing number of malignancies. While these medications utilize and enhance the immune system to treat malignancies, they can also have significant side effects, …
-
Cardiac Troponin I Mediates Autoimmune Mechanisms of Immune Checkpoint Inhibitor-Induced Myocarditis
Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer treatments and been used for previously difficult to treat cancer types. However, it comes at the expense of immune-related adverse events (irAEs), the most serious being myocarditis with many diagnosed patients later …
-
B Cell Tolerance and Immune-Related Adverse Events in Checkpoint Inhibitor Therapy
Immune Checkpoint Inhibitor (ICI) therapy has transformed oncology but is frequently limited by immune-related adverse events (irAEs). This thesis investigates potential mechanisms governing B cell tolerance during ICI therapy, specifically exploring whether pharmacological inhibition, …
-
Exercise as an adjunct therapy in melanoma patients undergoing checkpoint inhibitor therapy
… ± 13.6 years) with advanced melanoma receiving checkpoint inhibitors completed the 8-week single-group telehealth intervention. Intervention sessions were undertaken three times per week (24 sessions) and included supervised comprehensive balance, aerobic, and resistance exercises. The …
-
Investigating checkpoint inhibitor-induced gastrointestinal disease: comparisons with idiopathic ulcerative colitis and health
… A significant proportion of patients given these checkpoint inhibitors develop off-target inflammation in the colon (checkpoint inhibitor-induced colitis, CC). Ulcerative colitis (UC) is a well-characterized multisystem disorder, propagated by a combination of barrier defects, immune dysfunction …
-
Investigating the role of the gut microbiota on immune checkpoint inhibitor-mediated colitis
Immune checkpoint inhibitors (ICIs) have been revolutionary in the fight against cancer by recruiting the host immune system as an agent for attack on malignant cells. Unfortunately, immune-related adverse events (irAEs), including ICI-mediated colitis (IMC), are common side effects that result …
-
Novel and non-invasive markers of immune checkpoint inhibitor-associated acute kidney injury
INTRODUCTION: The introduction of immune checkpoint inhibitors (ICIs), a class of immunotherapy drugs, into the field of hematology/oncology has revolutionized the treatment of many malignancies. The benefits of these medications are enormous, but their use comes with some risks. Through systemic …
-
Explainable artificial intelligence to stratify pan-cancer patients for immune checkpoint inhibitor decision making
Immune checkpoints are a normal part of the immune system. It engages when proteins on the surface of immune cells called T cells recognize and bind to partner proteins on other cells, such as some tumor cells. Immune based therapies such as ICIs work by blocking checkpoint proteins from binding …
-
Leveraging proteomics and spatial transcriptomics in characterizing immune checkpoint inhibitor-associated acute kidney injury
… inability to reliably distinguish between immune checkpoint inhibitor-associated acute kidney injury (ICI-AKI) and AKI originating from non-ICI etiologies (non-ICI-AKI) has been associated with suboptimal clinical decisions and inferior outcomes among cancer patients. Utilizing the Olink …
-
Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare Expenditures among Older Patients with Late-stage Melanoma
… care with no added survival benefit, immune checkpoint inhibitors (ICI) changed the treatment landscape of late-stage melanoma in 2011. A key factor in determining the use of ICIs is the presence of pre-existing chronic conditions, which can influence the outcome. However, the prevalence of …
-
Identification of Immunogenic Cardiac Peptides Driving T-Cell Activation in Immune Checkpoint Inhibitor-Associated Myocarditis
1.1 Objective Immune Checkpoint Inhibitor (ICI) therapy has revolutionized cancer treatment by enhancing the immune system’s ability to target and destroy tumor cells. However, a major challenge of ICI therapy is the increased risk of inflammatory side effects, including myocarditis, which is the …
-
EXPLORING NOVEL CELLULAR THERPEUTICS FOR IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS: INVESTIGATING TIGIT OVEREXPRESSION IN T CELLS
Immune checkpoint inhibitors (ICIs) represent a promising class of monoclonal antibodies designed to target immune checkpoints (ICs) and their ligands, thereby counteracting cancer-induced T-cell suppression. Their application in various cancer types has demonstrated significant potential in …
-
Deep molecular profiling of the anti-tumour immune response in immune checkpoint inhibitor-treated oesophageal cancer
<p>Combined immune checkpoint inhibitors (ICI) with chemotherapy in advanced oesophageal cancer (OC) has shown survival benefit in phase III studies, resulting in ICI’s recent approval to treat advanced OC. The role of ICI in peri-operative OC is debated, and large clinical studies are ongoing. …
-
Checkpoint-Inhibitor assoziierte Pneumonitis beim Lungenkarzinom: Inzidenz, Risikofaktoren und Management – eine Analyse aus drei Berliner Lungenkrebszentren
Hintergrund Immuncheckpoint-Iinhibitoren (ICI) werden seit ihrer Erstzulassung 2015 in der Therapie des Nicht-kleinzelligen Lungenkarzinoms (NSCLC) stadienübergreifend eingesetzt. ICI-vermittelte Nebenwirkungen treten bei etwa 70% der Patient*innen auf, ein Drittel davon mit schwerem Verlauf. …
Page 1 of 9